| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 01/23/2003 | WO2002002771A3 Human sparc-homologous (hsparc-h1) gene and methods and uses thereof |
| 01/23/2003 | US20030018984 IGF-I expression system and methods of use |
| 01/23/2003 | US20030018189 Cyclic polyamines having total 9-24 members which have activity in against HIV-infected cells as well as other biological activity related to binding of ligands to chemokine receptors |
| 01/23/2003 | US20030018180 Secreted protein HFEAF41 |
| 01/23/2003 | US20030018041 Spiroindene and spiroindane compounds |
| 01/23/2003 | US20030017527 Human vanilloid receptor-like proteins |
| 01/23/2003 | US20030017220 Process for the extraction of valerian root |
| 01/23/2003 | US20030017141 Treatment of conditions characterized by a need to modulate migratory-cell movement associated with specific sites in a subject; isolating a stromal-cell-derived fugetactic agent |
| 01/23/2003 | US20030017120 Delivery of erectile dysfunction drugs through an inhalation route |
| 01/23/2003 | US20030017119 Aerosol comprises particles comprising at least 10 percent by weight of an opioid, and wherein the opioid is not heroin; opiods include morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, etc. |
| 01/23/2003 | US20030017118 An aerosol for inhalation therapy, wherein the aerosol comprises particles comprising at least 10 percent by weight of an antipsychotic such as olanzapine, trifluoperazine, haloperidol, loxapine, clozapine, quetiapine, promazine, etc. |
| 01/23/2003 | US20030017117 Delivery of analgesics through an inhalation route |
| 01/23/2003 | US20030017116 Delivery of sedative-hypnotics through an inhalation route |
| 01/23/2003 | US20030017115 Aerosol comprises particles comprising at least 10 percent by weight of a drug ester. |
| 01/23/2003 | US20030017114 Aerosol comprises particles of chlordiazepoxide, betahistine, clonidine, testosterone, conjugated estrogens, estrogen esters, estradiol, estradiol esters, ethinyl estradiol, ethinyl estradiol esters, or hyoscyamine. |
| 01/23/2003 | US20030015190 Delivery of compounds for the treatment of migraine through an inhalation route |
| 01/23/2003 | US20030015189 Delivery of antihistamines through an inhalation route |
| 01/23/2003 | CA2453389A1 Aerosol formulations of .delta.8 tetrahydrocannabinol |
| 01/23/2003 | CA2453090A1 A composition for use in prophylaxis and/or treatment |
| 01/23/2003 | CA2453083A1 A method for treatment and/or prophylaxis |
| 01/23/2003 | CA2452612A1 Novel anticonvulsant derivative salts |
| 01/23/2003 | CA2452544A1 Method for treating secondary tissue degeneration associated with central nervous system injury |
| 01/23/2003 | CA2448553A1 A pharmaceutical composition comprising a nicotinic receptor partial antagonist and an antiemetic agent of modulating cholinergic function |
| 01/23/2003 | CA2434303A1 Method for obtaining a tgf-beta enriched protein fraction in activated form, protein fraction and therapeutic applications |
| 01/22/2003 | EP1277474A1 Combination of arnica, ruscus and menthol |
| 01/22/2003 | EP1276872A2 A thymus expressed human cytochrome p450 (p450tec) |
| 01/22/2003 | EP1276856A1 Albumin fusion proteins |
| 01/22/2003 | EP1276849A2 Albumin fusion proteins |
| 01/22/2003 | EP1276764A1 Human polynucleotides, polypeptides, and antibodies |
| 01/22/2003 | EP1276731A2 Branched adamantyl and noradamantyl aryl- and aralkylpiperazines with serotonin 5-ht 1a activity |
| 01/22/2003 | EP1276392A2 Nutritional modules |
| 01/22/2003 | EP1222459A4 Crystallographic structure of the androgen receptor ligand binding domain |
| 01/21/2003 | US6509443 Amino acid residue located at position 63 of native-sequence human Insulin like Growth Factor-I is replaced with an alanine residue or amino acid residues at positions 1 and 70 are replaced with serine and valine respectively |
| 01/21/2003 | US6509328 Glutamate receptor antagonists |
| 01/21/2003 | US6509005 Nonozone depleting stable aerosol; treating nausea and vomiting associated with chemotherapy; muscle spasticity, pain, anorexia associated with AIDS wasting syndrome, epilepsy, glaucoma, bronchial asthma and mood disorders |
| 01/18/2003 | CA2352702A1 Novel human proton gated ion channel |
| 01/16/2003 | WO2003004613A2 Novel pgc-1 isoforms and uses therefor |
| 01/16/2003 | WO2003004608A2 Drug metabolizing enzymes |
| 01/16/2003 | WO2003004604A2 Phage displayed pdz domain ligands |
| 01/16/2003 | WO2003004527A2 Novel neurotrophic factors |
| 01/16/2003 | WO2003004497A1 Novel heterocyclic compound |
| 01/16/2003 | WO2003004493A1 Novel compounds, their preparation and use |
| 01/16/2003 | WO2003004487A1 Piperidine derivatives useful as modulators of chemokine receptor activity |
| 01/16/2003 | WO2003004475A1 Heterocyclic amines for the treatment of conditions associated with gsk-3 |
| 01/16/2003 | WO2003004472A1 Arylamines for the treatment of conditions associated with gsk-3 |
| 01/16/2003 | WO2003004467A2 Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use |
| 01/16/2003 | WO2002040016A3 Association of calpain inhibitors and reactive oxygen species trapping agents |
| 01/16/2003 | WO2002036107A3 Treatment of motor fluctuations with 5-hydroxytryptamine 1a receptor activity enhancing coumpounds |
| 01/16/2003 | WO2001098323A8 G-protein coupled receptors |
| 01/16/2003 | US20030013726 Sleep disorders; anxiolytic agents; muscle disease |
| 01/16/2003 | US20030013716 Pyrazino-pyridazine derivatives as ligands for gaba receptors |
| 01/16/2003 | US20030013710 Sexual disorders |
| 01/16/2003 | US20030013668 Antiarthritic agents; inflammatory bowel disease; multiple sclerosis |
| 01/16/2003 | US20030013637 Novel anti-autoimmune composition by inhibition of GRF action |
| 01/16/2003 | US20030012783 Interfere with the binding of a tumor necrosis factor receptor with its ligand; inhibiting the proliferation of tumor cells |
| 01/16/2003 | US20030012782 Method and composition for altering a T cell mediated pathology |
| 01/16/2003 | US20030012740 Aerosols especially containing benzotropine, pergolide, ropinerole, amantadine or deprenyl. |
| 01/16/2003 | US20030012737 Delivery of diphenhydramine through an inhalation route |
| 01/16/2003 | CA2453075A1 Drug metabolizing enzymes |
| 01/16/2003 | CA2452686A1 Arylamines for the treatment of conditions associated with gsk-3 |
| 01/16/2003 | CA2452609A1 Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use |
| 01/16/2003 | CA2452597A1 Piperidine derivatives useful as modulators of chemokine receptor activity |
| 01/16/2003 | CA2451395A1 Novel pgc-1 isoforms and uses therefor |
| 01/16/2003 | CA2450236A1 Phage displayed pdz domain ligands |
| 01/16/2003 | CA2448913A1 Sulfone containing bicyclic aromatic ring compounds, their preparation and use as nicotinic acetyl-chloine receptors |
| 01/15/2003 | EP1275659A1 Novel physiologically active peptides and use thereof |
| 01/15/2003 | EP1275646A1 Indolylpyrrole derivatives and cell death inhibitors |
| 01/15/2003 | EP1274849A2 Protein phosphatases |
| 01/15/2003 | EP1274720A1 Albumin fusion proteins |
| 01/15/2003 | EP1274719A2 Albumin fusion proteins |
| 01/15/2003 | EP1274710A2 Novel heteroaryl-diazabicycloalkanes |
| 01/15/2003 | EP1274701A1 Chemical compounds |
| 01/15/2003 | EP1274694A1 Novel compounds |
| 01/15/2003 | EP1274691A1 2-guanidino-4-arylchinazolines as nhe-3 inhibitors |
| 01/15/2003 | EP1274675A1 Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system |
| 01/15/2003 | EP1274430A2 Compounds for treating fibromyalgia and chronic fatigue syndrome |
| 01/15/2003 | EP1274428A2 Il-8 receptor antagonists |
| 01/15/2003 | EP1274415A2 Il-8 receptor antagonists |
| 01/15/2003 | EP1274413A2 Il-8 receptor antagonists |
| 01/15/2003 | EP1274407A2 Uses of ppar-gamma agonists in neutrophil-induced diseases |
| 01/15/2003 | EP0851756B1 Use of ondansetron in the manufacture of a medicament for the treatment of tremor |
| 01/15/2003 | CN1391571A Heterocyclic compounds and their use as medicines |
| 01/15/2003 | CN1391464A Formulation for menopausal women |
| 01/14/2003 | US6506891 Cell surface molecule-induced macrophage activation |
| 01/14/2003 | US6506874 Hypoglycemic agents; obesity, nervous system, cardiovascular, and kidney disorder treatment |
| 01/14/2003 | US6506779 Acetylene derivatives as anti-inflammatory/analgesic agents |
| 01/14/2003 | US6506772 Pharmaceutically active salts thereof with activity as adenosine receptor ligands are disclosed. These compounds are the adenosine receptor. |
| 01/14/2003 | US6506770 Antiviral compounds |
| 01/14/2003 | US6506399 Controlled release implantable drug delivery system composed of a plurality of botulinum toxin-incorporating polymeric microspheres. |
| 01/09/2003 | WO2003002739A1 Antisense oligonucleotide against human acetylcholinesterase (ache) and uses thereof |
| 01/09/2003 | WO2003002544A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | WO2003002140A1 Use of poly-glu, tyr and t cells treated therewith for neuroprotection therapy |
| 01/09/2003 | WO2003002118A1 Substituted 8-arylquinoline pde4 inhibitors |
| 01/09/2003 | WO2003002109A2 Use of tyrosine kinase inhibitors for treating autoimmune diseases |
| 01/09/2003 | WO2003001881A2 Cell-based high-throughput screening methods |
| 01/09/2003 | WO2002083716A3 Type b botulism toxin inhibitors |
| 01/09/2003 | WO2002080976A3 Hsa-free formulations of interferon-beta |
| 01/09/2003 | WO2002059111A3 Pyrazole compounds useful as protein kinase inhibitors |
| 01/09/2003 | WO2002046373A9 Method of collecting placental stem cells |
| 01/09/2003 | WO2002026997A3 Dsp-16 dual-specificity phosphatase |